Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Inspected “Wrong” Heparin API Manufacturer – Compliance Official

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA failed to inspect a Chinese API manufacturer that may be linked to a recent heparin safety scare because the wrong Chinese firm was entered into an agency database, a compliance official said Feb. 18

You may also be interested in...



Astellas Pharma Sells Grand Island, N.Y. Plant to APP Pharmaceuticals In Consolidation Move

TOKYO - Astellas Pharma said Sept. 5 it had sold its Grand Island, N.Y. plant that manufactures atopic dermatitis treatment Protopic (tacrolimus) to APP Pharmaceuticals of Schaumburg, Ill

Astellas Pharma Sells Grand Island, N.Y. Plant to APP Pharmaceuticals In Consolidation Move

TOKYO - Astellas Pharma said Sept. 5 it had sold its Grand Island, N.Y. plant that manufactures atopic dermatitis treatment Protopic (tacrolimus) to APP Pharmaceuticals of Schaumburg, Ill

U.S. FDA Move “Beyond Our Borders” Begins With China

Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.

Related Content

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel